Virtus LifeSci Biotech Products ETF(BBP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BBP Virtus LifeSci Biotech Products ETF

盘前交易 09-24 06:59:16 EDT

104.63

-3.03

-2.81%

最高107.89	最低104.02	成交量2.48万
今开107.89	昨收107.66	日振幅3.59%
总市值1.26亿	流通市值1.26亿	总股本120.00万
成交额260.07万	换手率2.07%	流通股本120.00万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BBP","market":"US","secType":"STK","nameCN":"Virtus LifeSci Biotech Products ETF","latestPrice":104.63,"timestamp":1790193600000,"preClose":107.66,"halted":0,"volume":24795,"delay":0,"changeRate":-0.02814415753297419,"floatShares":1200004,"shares":1200004,"eps":0,"marketStatus":"盘前交易","change":-3.03,"latestTime":"09-24 06:59:16 EDT","open":107.89,"high":107.89,"low":104.02,"amount":2600682,"amplitude":0.035946,"askPrice":166.36,"askSize":100,"bidPrice":87.8,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790256600000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":104.63,"sharesOutstanding":600004,"nav":107.513,"aum":129015878.88,"bidAskSpread":0.001976,"postHourTrading":{"tag":"盘后","latestPrice":104.63,"preClose":104.63,"latestTime":"17:08 EDT","volume":68,"amount":7057.14,"timestamp":1790197729192,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.5568625830872052,"impliedVol":0.2181,"impliedVolPercentile":0.336},"requestUrl":"/m/hq/s/BBP/tweets","defaultTab":"tweets","newsList":[{"id":"2669484013","title":"佳兆业健康(00876)：中文股份简称将更改为“青海生物制药”","url":"https://stock-news.laohu8.com/highlight/detail?id=2669484013","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669484013?lang=zh_cn&edition=full","pubTime":"2026-09-23 22:44","pubTimestamp":1790174658,"startTime":"0","endTime":"0","summary":"更改公司名称后，于香港联交所买卖股份之英文股份简称将由“KAISA HEALTH”更改为“QH BIO PHARMA”，而中文股份简称将由“佳兆业健康”更改为“青海生物制药”，自2026年9月28日上午九时正起生效。本公司于香港联交所之股份代号保持不变，仍为“876”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500165.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1230","BK1239","BBP","BK1121","IBBQ","02954","03069","MRNY","BK1154","00876","MRNX","BK1222"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669114208","title":"安进股价盘前大涨逾4%，受第三期临床试验结果提振。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669114208","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669114208?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:07","pubTimestamp":1790082475,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MRNX","IEHS","PBE","BIOY","IBBQ","BME","LU2473716301.USD","TBXU","IE00B4R5TH58.HKD","IYH","XPH","GNOM","PJP","TMED","WDNA","HELX","FTXH","MEDI","LU1992135472.HKD","IBRN","LU0058720904.USD","AZNH","LU2272731865.HKD","LU2272731782.SGD","RXL","XBIX","CANC","LU0122379950.USD","LFSC","MRNY","RSPH","SYNB","BIB","LU0320765992.SGD","LU0109394709.USD","SBIO","IBB","BBP","IDNA","PBPH","PSCH","LU2242646821.SGD","PPH","FBT","IEIH","AMGN","BBH","IE00B5TLWC47.USD","BK4585","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669169682","title":"公告精选︱科达制造：拟投资约45亿元建设年产50万吨石墨负极材料一体化项目；百花医药：不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2669169682","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669169682?lang=zh_cn&edition=full","pubTime":"2026-09-21 21:52","pubTimestamp":1789998737,"startTime":"0","endTime":"0","summary":"逸豪新材：拟定增募资不超过18亿元用于增资收购铭丰电子不低于78%股权","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6758003","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LFSC","BBP","BK0251","600499","WRND","BK4585","BK4588","BK0070","XLVI","BK0216","BK0155","SETM","GDOC","BK0188","GSKH","SBIO","IBB","BK0102","BIOY","PBE","600721","APXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669695531","title":"Cue生物制药公司股价回吐盘前涨幅，最新跌幅为3.3%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2669695531","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669695531?lang=zh_cn&edition=full","pubTime":"2026-09-21 21:47","pubTimestamp":1789998468,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BBP","IBBQ","MRNY","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669137049","title":"创新药热度飙升，关注100%创新药研发标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2669137049","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669137049?lang=zh_cn&edition=full","pubTime":"2026-09-21 13:55","pubTimestamp":1789970100,"startTime":"0","endTime":"0","summary":"MACD金叉信号形成，这些股涨势不错！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-21/doc-inisqkzy8876594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XLVI","IBBQ","BK4588","BBP","PBE","GSKH","BK1574","159992","SBIO","IBB","LNGR","BIOY","BK4585","APXH","LFSC","BK1161","06978","MEDX","WRND","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668075449","title":"生物制药企业Electra美股上市：募资3.5亿美元 上半年亏4891万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668075449","media":"雷递网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668075449?lang=zh_cn&edition=full","pubTime":"2026-09-20 10:32","pubTimestamp":1789871555,"startTime":"0","endTime":"0","summary":"生物制药企业Electra Therapeutics（股票代码：“ETRA”）日前在美国纳斯达克上市。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260920/6392549715050864394546786.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260920/6392549715050864394546786.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n35194/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BBP","MRNY","IPOS","IBBQ","03069","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股价盘后跌超2%，因其三期临床试验结果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666571008?lang=zh_cn&edition=full","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["WDNA","LU2322448957.HKD","PBPH","GNOM","LU2272731600.USD","LU1992135399.USD","LU2322448791.USD","MEDI","BBH","CANC","PSCH","AZNH","PBE","IDNA","IE00B5TLWC47.USD","LU2272731865.HKD","RXL","MRNX","FBT","BIB","IYH","LU1992135472.HKD","BK4588","BBP","IEHS","PPH","PJP","BME","IBRN","FTXH","LU2272731782.SGD","SYNB","HELX","TMED","IBB","LFSC","IEIH","LU2473716301.USD","SBIO","XBIX","XPH","BK4585","MRNY","RSPH","BIOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666563124","title":"118款生物药专利悬崖将至，中国药企业迎战MNC最大专利悬崖","url":"https://stock-news.laohu8.com/highlight/detail?id=2666563124","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666563124?lang=zh_cn&edition=full","pubTime":"2026-09-10 15:26","pubTimestamp":1789025185,"startTime":"0","endTime":"0","summary":"BCG合伙人杜菁博士指出，未来几年全球MNC将迎来史上最大专利悬崖，有118种生物制剂将会失去相应的专利保护，涉及2340亿美元市场。然而，目前这118款即将到期分子中，只有极少数在火热开发，大量缺口有待生物类似药填补。目前来说，创新药出海还没办法完成这个闭环，但生物类似药作为先头部队做出海试验，企业风险和获益会更高。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789025064363150858","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["IYH","RSPH","IHE","GSKH","JDOC","PJP","PBPH","FHLC","BBH","159839","PPH","TMED","TRUH","BME","BBP","FXH","APXH","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665936888","title":"复宏汉霖朱俊：未来所有制药企业都是AI制药企业，不存在不依赖AI的生物制药企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2665936888","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665936888?lang=zh_cn&edition=full","pubTime":"2026-09-05 14:04","pubTimestamp":1788588240,"startTime":"0","endTime":"0","summary":"朱俊坦言，尽管近年来国家批准的创新药数量已领先全球，但临床疗效的提升依然艰难。他强调，如果AI不能进一步赋能，生物医药产业将继续处于原始状态。未来，所有的制药企业都必须是AI制药企业，不存在不依赖AI的生物制药企业。朱俊总认为，在全球变局下，只要企业能够用好AI、抓住精准人群并解决真实的临床痛点，即使十个机会中只能抓住一个，也足以支撑企业的长远发展。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-09-05/doc-iniquccs3668085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BBP","BK1191","02696","IBBQ","BK1161","QTOC","VTHR","ARTY","HK0000320223.HKD","BK1574","CHAT","AGIX","HK0000306701.USD","HK0000320264.USD","03069","MRNX","HK0000165453.HKD","AIPO","MRNY","HK0000306685.HKD","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664337721","title":"康宁杰瑞生物制药回购56,000股 耗资492,430港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664337721","media":"财闻","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664337721?lang=zh_cn&edition=full","pubTime":"2026-09-04 20:53","pubTimestamp":1788526380,"startTime":"0","endTime":"0","summary":"9月4日，康宁杰瑞生物制药于2026年9月4日在香港联交所回购56,000股普通股，每股回购价格最高HKD8.8、最低HKD8.75，付出价格总额HKD492,430。回购股份拟持作库存股份，拟注销数目为0。回购后，已发行股份数目由968,056,697股减至968,000,697股，库存股份数目由6,325,000股增至6,381,000股，已发行股份总数维持974,381,697股。此次回购依据2026年6月12日获通过的回购授权进行，该授权可回购股份总数为96,850,669股。回购后暂止期截至2026年10月4日。呈交者为执行董事徐霆。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-04/doc-iniqsrak4001786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03069","CNAV","BBP","IBBQ","MRNX","MRNY","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664521258","title":"美股异动丨诺华制药涨超7%，多发性硬化症口服药后期临床试验结果积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2664521258","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664521258?lang=zh_cn&edition=full","pubTime":"2026-09-01 22:18","pubTimestamp":1788272338,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IBB","FTXH","MRNY","RXL","BK4585","CANC","IE00BJJMRZ35.SGD","GNOM","BME","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU2473716301.USD","IBRN","IYH","BK4588","LU0070302665.USD","RSPH","BK4007","SYNB","LFSC","LU0211331839.USD","IEIH","TMED","PPH","IDNA","LU2272731600.USD","LU2322448957.HKD","IE0009355771.USD","PJP","BBH","MRNX","BBP","XBIX","WDNA","IE00BJT1NW94.SGD","BIOY","PSCH","NVS","IEHS","XPH","BIB","AZNH","SBIO","PBPH","IE0002141913.USD","FBT","HELX","PBE","MEDX","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663282078","title":"药闻 | 英硅智能上市后首份半年报扭亏 创新药研发加速拥抱AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2663282078","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663282078?lang=zh_cn&edition=full","pubTime":"2026-08-31 15:35","pubTimestamp":1788161758,"startTime":"0","endTime":"0","summary":"新华财经上海8月31日电（记者杜康）作为AI制药领域代表性企业之一，英硅智能（03696.HK）日前发布2026年度中期业绩报告。上半年，公司实现总营收1.063亿美元，同比增长287.2%；净利润3554万美元，经调整净利润5123万美元，经营活动现金流转正。这是英硅智能上市后发布的首份半年报，公司也由此前的亏损转为盈利。从收入结构看，药物研发与管线开发仍是主要来源。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860072952.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860072952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LFSC","IPOS","IBB","GSKH","ARTY","APXH","BK4588","BBP","AGIX","CHAT","AIPO","XLVI","PBE","WRND","GDOC","BK4585","VTHR","QTOC","BIOY","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663238000","title":"武汉友芝友生物制药股份有限公司在香港暂停交易。","url":"https://stock-news.laohu8.com/highlight/detail?id=2663238000","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663238000?lang=zh_cn&edition=full","pubTime":"2026-08-31 08:36","pubTimestamp":1788136595,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MRNX","IBBQ","BBP","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044177","title":"联环药业上半年扭亏为盈 集采续采与创新药研发协同推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044177","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663044177?lang=zh_cn&edition=full","pubTime":"2026-08-30 21:12","pubTimestamp":1788095520,"startTime":"0","endTime":"0","summary":"业绩实现扭亏为盈经营基本面持续改善今年上半年，联环药业经营业绩实现明显改善。对此，联环药业正持续推进相关工作。值得注意的是，联环药业已经开始围绕创新药商业化进行营销体系布局。除LH-1801外，联环药业产品注册申报也取得阶段性进展。从核心产品稳定销售，到集采品种持续放量，再到创新药研发向上市申报环节推进，联环药业正在逐步形成多层次的业务增长支撑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK0239","BIOY","600513","SBIO","XLVI","BK4585","WRND","GSKH","BBP","LFSC","IBB","APXH","GDOC","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662058121","title":"海正药业与星际开发达成战略合作 布局太空生物制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2662058121","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662058121?lang=zh_cn&edition=full","pubTime":"2026-08-28 10:52","pubTimestamp":1787885542,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MRNY","BBP","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661672552","title":"阿巴斯生物制药宣布拟通过改良式“荷兰拍卖”要约收购，回购最高价值2.3亿美元的公司普通股。","url":"https://stock-news.laohu8.com/highlight/detail?id=2661672552","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661672552?lang=zh_cn&edition=full","pubTime":"2026-08-21 19:30","pubTimestamp":1787311853,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BBP","MRNX","EVNT","MRNY","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660431564","title":"骏利亨德森投资：专利到期倒逼药企扩张 生物科技并购、IPO市场同步复苏","url":"https://stock-news.laohu8.com/highlight/detail?id=2660431564","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660431564?lang=zh_cn&edition=full","pubTime":"2026-08-19 16:06","pubTimestamp":1787126785,"startTime":"0","endTime":"0","summary":"骏利亨德森投资称，尽管利率较市场年初的预期为高，但生物科技行业交易活动的增长动力持续不减。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260819/20260819160606_21666.png?x-oss-process=image/format,jpg/quality,q_60","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260819/20260819160606_21666.png?x-oss-process=image/format,jpg/quality,q_60"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481902.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4588","MRNX","BK4582","PBE","BBC","BIS","SPCK","IJT","JDOC","IWO","QSML","IAI","GTPE","MRNY","BIB","IYG","IBB","BBP","FBT","IBBJ","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660415061","title":"杭萧钢构等投资成立生物制药公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2660415061","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660415061?lang=zh_cn&edition=full","pubTime":"2026-08-19 09:44","pubTimestamp":1787103899,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MRNX","IBBQ","MRNY","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660317064","title":"国泰海通｜医药：大药诞生之自免系列四：“专利悬崖”将至，MNC看好哪些下一代自免大药","url":"https://stock-news.laohu8.com/highlight/detail?id=2660317064","media":"国泰君安证券研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660317064?lang=zh_cn&edition=full","pubTime":"2026-08-16 22:18","pubTimestamp":1786889880,"startTime":"0","endTime":"0","summary":"自免“专利悬崖”开启，MNC正积极布局下一代接棒管线仅考虑各家MNC核心自免资产，2026H1市场销售规模超700亿美元，同比增长近9%。报告名称：大药诞生之自免系列四：“专利悬崖”将至，MNC看好哪些下一代自免大药；报告日期：2026.08.14 报告作者：汪晋（分析师），登记编号：S0880526030004余克清（分析师），登记编号：S0880525120002余文心（分析师），登记编号：S0880525040111重要提醒本订阅号所载内容仅面向国泰海通证券研究服务签约客户。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650540470&idx=3&sn=7042e4acd674daff990a886cbfb65213&chksm=89513c50607e74835d610e4a7523db029bc5793640c09ee0ad94e7debc44c9117f4dc88efa10&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["02611","BK1574","TRUH","FXH","BK1161","BK0183","JDOC","PPH","IHE","BK0028","FHLC","BK0276","BK0184","BME","RSPH","BBP","601211","BK0012","BK0201","BK1147","09939","BK1564","GSKH","159938","BK1515","IYH","PBPH","PJP","TMED","APXH","BBH","MEDI","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659504119","title":"中国银河证券：实验动物为创新药研发刚需 小鼠+猴双主线高景气","url":"https://stock-news.laohu8.com/highlight/detail?id=2659504119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659504119?lang=zh_cn&edition=full","pubTime":"2026-08-14 15:07","pubTimestamp":1786691225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，实验动物为创新药研发刚需，行业壁垒深厚，两大细分赛道具备中长期成长逻辑：人源化小鼠赛道成长确定性更强、周期波动平缓;实验猴赛道供给约束强，短期价格上行带来显著业绩弹性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","601881","BK1564","PBE","BK1147","GSKH","APXH","06881","XLVI","BIOY","161027","WRND","LFSC","BBP","BK4588","IBB","GDOC","BK4585","SBIO","BK0276"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0258},{"period":"1month","weight":-0.0213},{"period":"3month","weight":0.1209},{"period":"6month","weight":0.331},{"period":"1year","weight":0.499},{"period":"ytd","weight":0.3093}],"compareEarnings":[{"period":"1week","weight":0.0182},{"period":"1month","weight":0.0057},{"period":"3month","weight":0.0456},{"period":"6month","weight":0.2109},{"period":"1year","weight":0.1577},{"period":"ytd","weight":0.126}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.013251},{"month":2,"riseRate":0.416667,"avgChangeRate":0.009089},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.010237},{"month":4,"riseRate":0.583333,"avgChangeRate":0.00248},{"month":5,"riseRate":0.583333,"avgChangeRate":0.009273},{"month":6,"riseRate":0.916667,"avgChangeRate":0.050034},{"month":7,"riseRate":0.666667,"avgChangeRate":0.017627},{"month":8,"riseRate":0.666667,"avgChangeRate":0.026611},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.015636},{"month":10,"riseRate":0.636364,"avgChangeRate":-0.014134},{"month":11,"riseRate":0.909091,"avgChangeRate":0.065286},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.005253}],"exchange":"ARCA","name":"Virtus LifeSci Biotech Products ETF","nameEN":"Virtus LifeSci Biotech Products ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Virtus LifeSci Biotech Products ETF(BBP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Virtus LifeSci Biotech Products ETF(BBP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Virtus LifeSci Biotech Products ETF,BBP,Virtus LifeSci Biotech Products ETF股票,Virtus LifeSci Biotech Products ETF股票老虎,Virtus LifeSci Biotech Products ETF股票老虎国际,Virtus LifeSci Biotech Products ETF行情,Virtus LifeSci Biotech Products ETF股票行情,Virtus LifeSci Biotech Products ETF股价,Virtus LifeSci Biotech Products ETF股市,Virtus LifeSci Biotech Products ETF股票价格,Virtus LifeSci Biotech Products ETF股票交易,Virtus LifeSci Biotech Products ETF股票购买,Virtus LifeSci Biotech Products ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Virtus LifeSci Biotech Products ETF(BBP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Virtus LifeSci Biotech Products ETF(BBP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}